# A Study of Belzutifan (MK-6482) in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell Carcinoma (MK-6

Source: https://onco.cc/trials/nct05468697/  
OnCo record `nct05468697` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Belzutifan, Palbociclib in renal cell carcinoma, run by Merck Sharp & Dohme LLC, active and no longer recruiting.

## Summary

A Study of Belzutifan (MK-6482) in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell Carcinoma (MK-6482-024/LITESPARK-024) is a phase 1/2 interventional study registered as NCT05468697 by Merck Sharp & Dohme LLC, with 60 participants planned, started 2022-08-10 and due to reach its primary completion in 2026-10-22. Interventions recorded: Belzutifan, Palbociclib. Conditions listed: Renal Cell Carcinoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT05468697
- Phase: 1/2
- Setting: A Multicenter, Open-label, Randomized, Phase 1/2 Study of Belzutifan in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell Carcinoma
- Sponsor: Merck Sharp & Dohme LLC
- Enrolled: 60

## Sources

- ClinicalTrials.gov NCT05468697: https://clinicaltrials.gov/study/NCT05468697

## Connected records

- cancers: [Renal cell carcinoma](https://onco.cc/cancers/rcc/)
- drugs: [Belzutifan](https://onco.cc/drugs/belzutifan/), [Palbociclib](https://onco.cc/drugs/palbociclib/)
- companies: [Merck & Co. (MSD)](https://onco.cc/companies/merck/)

---
JSON: https://onco.cc/api/v1/entities/nct05468697.json